Navigation Links
MedImmune In-Licenses Clinical-Stage Anti-Inflammatory Monoclonal Antibody From Amgen
Date:1/7/2011

GAITHERSBURG, Md., Jan. 7, 2011 /PRNewswire/ -- MedImmune today announced an in-licensing agreement with Amgen for a novel monoclonal antibody targeting the IL-1 pathway.  The antibody, AMG 108, a fully human monoclonal antibody to the IL-1 receptor, has been studied in multiple phase 1 and phase 2 clinical trials and will now be explored by MedImmune for its potential against certain inflammatory diseases.  

Under the terms of the agreement, Amgen grants MedImmune rights to develop AMG 108 worldwide, outside of Japan.  Terms of the agreement include an upfront payment, development-related milestone payments for multiple indications, and royalties upon sale of a commercial product.  Financial details will not be disclosed.

"Recent data indicates the importance of the IL-1 pathway in a variety of inflammatory conditions, and AMG 108 represents a compelling opportunity to explore this antibody's activity against various diseases for which patients need new treatment options," said Bahija Jallal, executive vice president of research and development at MedImmune.  

The exploration of AMG 108 is strategically aligned with the organization's commitment to advancing promising biological assets from both internal and external sources.

About MedImmune

MedImmune, the worldwide biologics unit for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,500 employees worldwide and is headquartered in Gaithersburg, Maryland. For more information, visit MedImmune's website at www.medimmune.com.


'/>"/>
SOURCE MedImmune
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. MedImmune Announces Winners of the 5th Annual Respiratory, Inflammation and Autoimmunity Research Abstract Competition
2. MedImmune Focused on Revolutionizing Cancer Care
3. MedImmune to Present Five Abstracts on RSV at Pediatric Academic Societies Annual Meeting
4. MedImmune to Present Data on RSV and Influenza at 2009 American Academy of Pediatrics National Conference & Exhibition
5. MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants
6. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
7. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
8. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
9. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
10. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
11. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... , May 23, 2016 Diplomat Pharmacy, Inc. (NYSE: ... Fellowship and Internship programs. The hands-on learning experience is ... The full-time, paid Fellowship and Internship ... . Fellows and interns are provided optional housing ... Flint at the Riverfront Residence Hall to ...
(Date:5/23/2016)... The World Health Organization (WHO) expanded the Intended ... adolescents aged 13 years, and above. Effective immediately, the PrePex ... and adolescent males in the 14 priority countries in Southern ... first male circumcision device to receive WHO Prequalification on 31 ... said: " The expanded use of PrePex ...
(Date:5/23/2016)... 2016 The global  reprocessed medical ... by 2022, according to a new study by Grand ... coupled with the lack of centralized support for waste ... the demand for reprocessed medical devices market. Additionally, the ... that of the original device is the high impact ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... ... and clinical practice of radiosurgery, is recognizing five medical residents and students for ... stereotactic body radiotherapy (SBRT). The awards will be presented at the 2016 SRS/SBRT ...
(Date:5/24/2016)... ... 24, 2016 , ... Bio-Logic Aqua® Research Water Life Science® ... a trainer for Ageless Grace ( http://www.agelessgrace.com ) to discuss healthier lifestyles, especially ... 2016. , Formerly a Northwestern University Literature Professor, Kinst gravitated to her career ...
(Date:5/24/2016)... ... May 24, 2016 , ... In light of recent ... of the potential of contaminated well water throughout the Houston area. , Heavy floodwaters ... well water that’s exposed to contaminants. Residents may not even be aware of the ...
(Date:5/24/2016)... ... 2016 , ... The Dream Builders Project, a 501(c)3 nonprofit organization based in ... in Tijuana, Mexico on Saturday, May 21st. The volunteers took the children out for ... More than 15 volunteers traveled from Los Angeles to Tijuana, Mexico for the day ...
(Date:5/24/2016)... Greenwich, Connecticut (PRWEB) , ... May 24, 2016 ... ... of Lyme and tick-borne disease research and education, today announced that it has ... and CEO of the Bonnie J. Addario Lung Cancer Foundation (ALCF) in San ...
Breaking Medicine News(10 mins):